c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 385-390

  Jung, Joohee ^a   Kim, Eun Jin ^a   Chung, Hye Kyung ^a   Park, Heon Joo ^b   Jeong, Seong Yun ^a   Choi, Eun Kyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

C Myc; Fractionated radiation; Non small cell lung cancer; Proteasome inhibitor; Radio sensitizer

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; ONCOGENE C MYC; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DOWN-REGULATION; HUMANS; LEUPEPTINS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MYC; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862907711     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1205     Document Type: Article

References (27)

1. Jemal A, Thun MJ, Ries LA, et al: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694, 2008.
2. O'Rourke N, Roque IFM, Farre Bernado N and Macbeth F: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 6: CD002140, 2010.
3. Overgaard J: Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25: 4066-4074, 2007.
4. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945, 1990. (Pubitemid 20332333)
5. Sandler A: State-of-the-art treatment for advanced non-small-cell lung cancer. Oncology 17: 15-22, 2003.
6. Choi EK, Terai K, Ji IM, et al: Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 9: 634-642, 2007. (Pubitemid 47328082)
7. Jeong SY, Park SJ, Yoon SM, et al: Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release 139: 239-245, 2009.
8. Goktas S, Baran Y, Ural AU, et al: Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology 75: 793-798, 2010.
9. Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645, 1999. (Pubitemid 29437352)
10. Han YH, Moon HJ, You BR and Park WH: The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner. Oncol Res 18: 315-322, 2010.
11. Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657, 2008. (Pubitemid 351469448)
12. Van Waes C, Chang AA, Lebowitz PF, et al: Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412, 2005. (Pubitemid 41628035)
13. Russo SM, Tepper JE, Baldwin AS Jr, et al: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193, 2001.
14. Pajonk F, van Ophoven A, Weissenberger C and McBride WH: The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 5: 76, 2005.
15. Warren G, Grimes K, Xu Y, Kudrimoti M and St Clair W: Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep 15: 1287-1291, 2006.
16. Grimes KR, Daosukho C, Zhao Y, Meigooni A and St Clair W: Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol 27: 1047-1052, 2005.
17. Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990, 2008.
18. Pelengaris S, Khan M and Evan G: c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776, 2002. (Pubitemid 37328911)
19. Cervello M, Giannitrapani L, La Rosa M, et al: Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med 13: 741-748, 2004.
20. Iliakis G, Wang Y, Guan J and Wang H: DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22: 5834-5847, 2003. (Pubitemid 37176704)
21. Dewey WC, Ling CC and Meyn RE: Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33: 781-796, 1995.
22. Ahn JY, Schwarz JK, Piwnica-Worms H and Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60: 5934-5936, 2000.
23. Fernandez-Capetillo O, Chen HT, Celeste A, et al: DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 4: 993-997, 2002. (Pubitemid 35469431)
24. Lavin MF, Birrell G, Chen P, Kozlov S, Scott S and Gueven N: ATM signaling and genomic stability in response to DNA damage. Mutat Res 569: 123-132, 2005. (Pubitemid 39643262)
25. Matsuoka S, Huang M and Elledge SJ: Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897, 1998. (Pubitemid 28555269)
26. Dancea HC, Shareef MM and Ahmed MM: Role of radiation-induced TGF-beta signaling in cancer therapy. Mol Cell Pharmacol 1: 44-56, 2009.
27. Jung P and Hermeking H: The c-MYC-AP4-p21 cascade. Cell Cycle 8: 982-989, 2009.